Slide 1: First Quarter March 31, 2025 Investors Call
May 2025 First Quarter March 31, 2025 Investors Call
Slide 2: Forward-Looking Statement
FORWARD - LOO K I NG STATEM ENT This presentation is not intended to provide investment or medical advice . It should be noted that some products under development described herein have not been found safe or effective by any regulatory agency and are not approved for any use outside of clinical tri
Slide 3: Q1-25 Continuing the Growth
GROSS MARGIN REVENUE 3bp 2024 44% 2025 47% 17% 2024 $37.7 2025 $44.0 Adj. EBITDA EPS 54% 2024 $7.5 2025 $11.6 75% 2024 $0.04 2025 $0.07 Q1 - 25 CONTINUING THE GROWTH YoY DOUBLE DIGIT REVENUE AND PROFITABLE INCREASE Paid special cash dividend of $0.20 per share (totaling approximately $11.5M) on Apri
Slide 4: FDA-Approved Specialty Plasma Products
6 FDA - APPROVED SPECIALTY PLASMA PRODUCTS KEY FOCUS ON TRANSPLANTS & RARE CONDITIONS KEDRAB® [Rabies Immune Globulin (Human)] Post exposure prophylaxis of rabies infection CYTOGAM® [Cytomegalovirus Immune Globulin (Human)] Prophylaxis of CMV disease associated with transplants HEPGAM B® [Hepatitis
Slide 5: Annual Double-Digit Growth Trajectory
6 18 24 34 38 - 42 2021 2022 2023 2024 2025 2025 represents annualguidance 104 129 142 161 1 78 - 182 2021 2022 2023 2024 2025 2025 represents annualguidance ADJUSTED EBITDA US$M 61% CAGR ANNUAL DOUBLE - DIGIT GROWTH TRAJECTORY REVENUES US$M 15% CAGR Quarter - End Strong Cash Position of $76.3 Milli
Slide 6: Delivering on Our Commitments
DELIVERING ON OUR COMMITMENTS
Slide 7: Kamada's Roadmap for Continued Annual Double-Digit Growth
KAMADA’S ROADMAP FOR CONTINUED ANNUAL DOUBLE - DIGIT GROWTH M &A T r a ns a c ti o n s Support growth through M&A transactions Organic Growth Portfolio of 6 FDA - approved products; Over 30 territories; and Distribution portfolio in Israel Plasma C o l l e c ti o n Centers Each new center expected t
Slide 8: CYTOGAM CMV Immune Globulin
CYTOGAM CMV IMMUNE GLOBULIN CYTOGAM is the only plasma - derived IgG approved in the U.S. and Canada for prophylaxis of CMV disease after Solid Organ Transplantation. CMV is the leading cause for organ rejection post - transplant Launched, in collaboration with multiple KOLs, a post - marketing rese
Slide 9: Distribution Segment Growth
DISTRIBUTION SEGMENT GROWTH More than 25 products exclusively licensed from leading international pharmaceutical companies, marketed in the Israeli market EXCLUSIVE DISTRIBUTOR IN ISRAEL FOR LEADING BIOPHARMACEUTICAL COMPANIES EXPENDING THE DISTRIBUTION SEGMENT MODEL TO THE MENA REGION Key areas: pl
Slide 10: M&A Transactions
M&A TRANSACTIONS EXPECT TO SECURE NEW BUSINESS DEVELOPMENT AND M&A TRANSACTIONS DURING 2025; LEVERAGING OVERALL FINANCIAL STRENGTH AND COMMERCIAL INFRASTRUCTURE Exploring strategic business development opportunities to identify potential acquisition or in - licensing to accelerate long - term growth
Slide 11: Kamada Plasma: Expanding Vertical Integration & Revenue Growth
KAMADA PLASMA EXPANDING VERTICAL INTEGRATION & REVENUE GROWTH Collecting hyper - immune plasma for our specialty IgG products and normal source plasma (NSP) to support revenue growth Operating three plasma collection centers in Texas; Houston, San Antonio and Beaumont At full collection capacity, ea
Slide 12: Inhaled AAT Phase 3 Pivotal Study
FDA reconfirmed overall study design, endorsed positive safety data to date, and confirmed its agreement with our proposed P - value of 0.1 in evaluating the trial’s efficacy primary endpoint $2 Billion A substantial market opportunity (2028) 1 Based on expected changes to the statistical analysis p
Slide 13: Q1 2025 Financial Details
DETAILS Q1/24 Q1/25 US $ M Driven by KEDRAB®, VARIZIG®, GLASSIA® Royalties and GLASSIA sales 33.8 40.0 PROPRIETARY 4.0 4.0 DISTRIBUTION 17% YoY increase 37.7 44.0 TOTAL REVENUES 16.8 20.7 GROSS PROFIT 3 basis point increase YoY 44% 47% GROSS MARGIN (12.7) (13.0) OPEX 2.4 4.0 NET PROFIT 54% YoY incre
Slide 14: Kamada - A Global Biopharmaceutical Company
KEDRAB ® CYTOGA M® HEPGAM B® VARIZIG® WINRHO® GLASSIA® KAMADA - A GLOBAL BIOPHARMACEUTICAL COMPANY 6 FDA - Approved Products 15% CAGR (from 2021) $178 - 182M 2025 Revenues Guidance $38 - 42M 2025 Adj. EBIDTA Guidance 4 Pillars of Growth A LEADER IN SPECIALTY PLASMA THERAPIES, WITH A PORTFOLIO OF MAR
Slide 15: Thank You
THANK YOU www.kamada.com
Slide 16: Non-IFRS Measures – Adjusted EBITDA
NON - IFRS MEASURES – ADJUSTED EBITDA Q1/24 Q1/25 US $ M 2.4 4.0 NET PROFIT 0.1 2.6 TAXES ON INCOME 1.8 1.8 REVALUATION OF ACQUISITION RELATED CONTINGENT CONSIDERATION (0.2) (0.6) OTHER FINANCIAL EXPENSE, NET 1.8 1.8 AMORTIZATION OF ACQUISITION RELATED INTANGIBLE ASSETS 1.5 1.8 OTHER DEPRECIATION AN